Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Sees Large Decrease in Short Interest

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totaling 8,701 shares, a drop of 36.0% from the September 30th total of 13,598 shares. Based on an average daily volume of 35,468 shares, the short-interest ratio is currently 0.2 days. Currently, 0.7% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings cut Aspire Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 25th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has an average rating of “Sell”.

Aspire Biopharma Price Performance

Aspire Biopharma stock opened at $7.27 on Wednesday. The company’s 50 day simple moving average is $8.53 and its 200 day simple moving average is $17.18. Aspire Biopharma has a fifty-two week low of $3.31 and a fifty-two week high of $431.88.

About Aspire Biopharma

Aspire Biopharma, Inc is a clinical-stage biopharmaceutical company developing orally administered therapies using a proprietary fast-dissolving tablet and sublingual delivery platform. The company’s technology is designed to deliver active ingredients through the tissues beneath the tongue, potentially allowing rapid absorption while reducing reliance on the gastrointestinal tract and first-pass metabolism.

Aspire’s lead development program has focused on an orally dissolvable epinephrine product intended for the emergency treatment of severe allergic reactions, including anaphylaxis.